Answers are grounded in this paper and cite their sources.
Background/Aim Colorectal cancer (CRC) is a leading cause of cancer‐related mortality worldwide. This study aimed to identify tumor‐associated genes in CRC and explore potential therapeutic agents by analyzing chromosomal amplification. Methods DNA copy number variation (CNV) and mRNA expression data from The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) were analyzed. We focused on cytochrome c oxidase assembly factor 19 (COX19) as a candidate tumor‐associated gene and examined its clinicopathological and prognostic relevance. Single‐cell RNA sequencing and immunohistochemical analyses were performed. Pathway and drug sensitivity analyses were conducted, followed by in vitro validation of candidate compounds. Results COX19, a mitochondrial complex IV assembly factor, was significantly amplified and overexpressed in CRC. High COX19 expression correlated with poor prognosis and was predominantly observed in tumor epithelial cells. Gene set enrichment analysis (GSEA) suggested suppression of apoptosis in COX19 ‐high tumors. Drug sensitivity analysis identified olmesartan as a candidate therapeutic agent. Olmesartan suppressed the proliferative capacity of COX19 ‐overexpressing CRC cells, whereas COX19 knockout reduced sensitivity to olmesartan. Olmesartan also increased miR‐205‐3p expression, and miR‐205‐3p inhibition partially attenuated its antiproliferative effect. Conclusion COX19 may be a tumor‐associated gene linked to tumor progression and poor prognosis in CRC. Olmesartan may represent a potential therapeutic candidate for COX19 ‐high CRC. Its antiproliferative effects may involve miR‐205‐3p, although the underlying mechanism requires further validation.
No takes yet. Share an insight, caveat, or question.
Kawata et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: